Drugs / Tiotropium bromide and olodaterol hydrochloride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07267130 | Nov 2025 → Oct 2026 expected | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiotropium bromide and olodaterol hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07267130 ↗ |
| Known as | Spiolto Respimat | “Spiolto® Respimat® : Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg)” NCT07267130 ↗ |
| Action | Inhibit | “Tiotropium bromide and olodaterol hydrochloride inhalation spray is a targeted inhibitor” NCT07267130 ↗ |
| Route | Inhaled | “Tiotropium bromide and olodaterol hydrochloride inhalation spray” NCT07267130 ↗ |